Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a menin-blocking drug outsmart stubborn leukemia?

NCT ID NCT07722312

Not yet recruiting Disease control Sponsor: Servier Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1c mutation). The goal is to see if the drug is safe and can shrink or eliminate the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental menin inhibitor drug called S243249
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat acute leukemias that have specific genetic changes.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia acute myeloid leukemia with mutated NPM1 acute myeloid leukemia, MLL gene rearrangement mixed phenotype acute leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY ACUTE LEUKEMIA RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.